Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.
about
Advances in antibiotic therapy in the critically illTherapeutic drug monitoring of amikacin in septic patients.An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration.Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration.Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltrationInfluence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes.Pharmacological considerations for the proper clinical use of aminoglycosides.Year in review 2010: Critical Care--Infection.Treatment option for sepsis in children in the era of antibiotic resistance.Phenotypic and molecular characterization of antimicrobial resistance and virulence factors in Pseudomonas aeruginosa clinical isolates from Recife, State of Pernambuco, Brazil.A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study.Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis.Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients.
P2860
Q26749328-18D5976A-2087-496D-82C2-A4C5FA922DA9Q33754166-8F73BDBF-9AF2-458E-8C03-92A53D0B1999Q34470946-CCABA508-A08A-4A64-AADF-86C66176C1DDQ35270646-A802E74E-330F-4EFB-B2CD-1C18A4CD26AEQ35598435-996D6788-CBE9-4AB2-889E-3D2CC7FF2039Q36172460-135A95CB-2470-4AF2-8068-ADA1F74F7F90Q37894694-588DF20E-D20F-486F-BBCE-89C5022D9EC6Q37956403-0501911F-3E0F-4005-92C1-D8A02AD7CB53Q37966018-35185B9A-DEB8-48E3-83F3-4461223402F4Q38246118-69F9918C-47D0-4D22-8F93-3F2B9F4E14B8Q39113907-53B1D9D0-131A-4260-B304-1AA1C7C32A43Q40809870-E7D435E0-F6E3-4B0D-83AF-82DA3692FE66Q41755724-96ECD2B2-78C0-4F8B-923E-DF1085CAC0B9Q47661746-C79CC43A-13B6-45C0-9913-5C7754DA73AEQ49894608-E59C93B6-AE01-4C3C-B35D-A010345CD08E
P2860
Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.
@ast
Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.
@en
Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.
@nl
type
label
Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.
@ast
Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.
@en
Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.
@nl
prefLabel
Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.
@ast
Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.
@en
Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.
@nl
P2093
P2860
P356
P1476
Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.
@en
P2093
Brice Layeux
David Fagnoul
Fabio Silvio Taccone
Frédérique Jacobs
P2860
P304
P356
10.1128/AAC.00441-10
P407
P577
2010-09-07T00:00:00Z